Details of the Drug

General Information of Drug (ID: DM741KF)

Drug Name

BNT116

Indication

Disease Entry	ICD 11	Status	REF
Non-small-cell lung cancer	2C25	Phase 2	[1]
------------------------------------------------------------------------------------

Drug Type

Vaccine

Cross-matching ID

References

1	ClinicalTrials.gov (NCT05557591) A Phase 2 Study of Cemiplimab (Anti-PD-1 Antibody) in Combination With BNT116 (FixVac Lung) Versus Cemiplimab Monotherapy in First-Line Treatment of Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) With Tumors Expressing PD-L1 >=50%. U.S.National Institutes of Health.